Literature DB >> 19734051

Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.

Lei Du-Cuny1, Zuohe Song, Sylvestor Moses, Garth Powis, Eugene A Mash, Emmanuelle J Meuillet, Shuxing Zhang.   

Abstract

Computational modeling continues to play an important role in novel therapeutics discovery and development. In this study, we have investigated the use of in silico approaches to develop inhibitors of the pleckstrin homology (PH) domain of AKT (protein kinase B). Various docking/scoring schemes have been evaluated, and the best combination was selected to study the system. Using this strategy, two hits were identified and their binding behaviors were investigated. Robust and predictive QSAR models were built using the k nearest neighbor (kNN) method to study their cellular permeability. Based on our in silico results, long flexible aliphatic tails were proposed to improve the Caco-2 penetration without affecting the binding mode. The modifications enhanced the AKT inhibitory activity of the compounds in cell-based assays, and increased their activity as in vivo antitumor testing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734051      PMCID: PMC2808703          DOI: 10.1016/j.bmc.2009.08.022

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  48 in total

1.  Novel variable selection quantitative structure--property relationship approach based on the k-nearest-neighbor principle

Authors: 
Journal:  J Chem Inf Comput Sci       Date:  2000-01

2.  Three-dimensional quantitative structure-permeability relationship analysis for a series of inhibitors of rhinovirus replication.

Authors:  S Ekins; G L Durst; R E Stratford; D A Thorner; R Lewis; R J Loncharich; J H Wikel
Journal:  J Chem Inf Comput Sci       Date:  2001 Nov-Dec

3.  Rational selection of training and test sets for the development of validated QSAR models.

Authors:  Alexander Golbraikh; Min Shen; Zhiyan Xiao; Yun-De Xiao; Kuo-Hsiung Lee; Alexander Tropsha
Journal:  J Comput Aided Mol Des       Date:  2003 Feb-Apr       Impact factor: 3.686

4.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

5.  Chemometric analysis of ligand receptor complementarity: identifying Complementary Ligands Based on Receptor Information (CoLiBRI).

Authors:  Scott Oloff; Shuxing Zhang; Nagamani Sukumar; Curt Breneman; Alexander Tropsha
Journal:  J Chem Inf Model       Date:  2006 Mar-Apr       Impact factor: 4.956

Review 6.  Membrane recognition by phospholipid-binding domains.

Authors:  Mark A Lemmon
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02       Impact factor: 94.444

7.  Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.

Authors:  Emmanuelle J Meuillet; Daruka Mahadevan; Hariprasad Vankayalapati; Margareta Berggren; Ryan Williams; Amy Coon; Alan P Kozikowski; Garth Powis
Journal:  Mol Cancer Ther       Date:  2003-04       Impact factor: 6.261

8.  Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change.

Authors:  Christine C Milburn; Maria Deak; Sharon M Kelly; Nick C Price; Dario R Alessi; Daan M F Van Aalten
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

9.  Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

Authors:  Amrita V Kamath; Jian Wang; Francis Y Lee; Punit H Marathe
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-11       Impact factor: 3.333

Review 10.  A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities.

Authors:  Alfonso Bellacosa; Joseph R Testa; Robert Moore; Lionel Larue
Journal:  Cancer Biol Ther       Date:  2004-03-11       Impact factor: 4.742

View more
  16 in total

1.  Accurate prediction of the bound form of the Akt pleckstrin homology domain using normal mode analysis to explore structural flexibility.

Authors:  Hoang T Tran; Shuxing Zhang
Journal:  J Chem Inf Model       Date:  2011-08-25       Impact factor: 4.956

Review 2.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Development of sulfonamide AKT PH domain inhibitors.

Authors:  Ali Md Ahad; Song Zuohe; Lei Du-Cuny; Sylvestor A Moses; Li Li Zhou; Shuxing Zhang; Garth Powis; Emmanuelle J Meuillet; Eugene A Mash
Journal:  Bioorg Med Chem       Date:  2011-02-01       Impact factor: 3.641

4.  Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.

Authors:  Caroline A Larregieu; Leslie Z Benet
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

5.  Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors.

Authors:  Ribai Yan; Hsiao-Ching Chuang; Naval Kapuriya; Chih-Chien Chou; Po-Ting Lai; Hsin-Wen Chang; Chia-Ning Yang; Samuel K Kulp; Ching-Shih Chen
Journal:  J Med Chem       Date:  2015-02-27       Impact factor: 7.446

Review 6.  Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.

Authors:  E J Meuillet
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 7.  Recent development of anticancer therapeutics targeting Akt.

Authors:  John K Morrow; Lei Du-Cuny; Lu Chen; Emmanuelle J Meuillet; Eugene A Mash; Garth Powis; Shuxing Zhang
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-01       Impact factor: 4.169

8.  A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.

Authors:  Lei Du-Cuny; Lu Chen; Shuxing Zhang
Journal:  J Chem Inf Model       Date:  2011-10-13       Impact factor: 4.956

9.  Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.

Authors:  Emmanuelle J Meuillet; Song Zuohe; Robert Lemos; Nathan Ihle; John Kingston; Ryan Watkins; Sylvestor A Moses; Shuxing Zhang; Lei Du-Cuny; Roy Herbst; Jörg J Jacoby; Li Li Zhou; Ali M Ahad; Eugene A Mash; D Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

10.  Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.

Authors:  Chia-Hsin Chan; John Kenneth Morrow; Chien-Feng Li; Yuan Gao; Guoxiang Jin; Asad Moten; Loren J Stagg; John E Ladbury; Zhen Cai; Dazhi Xu; Christopher J Logothetis; Mien-Chie Hung; Shuxing Zhang; Hui-Kuan Lin
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.